Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108159 · ClinicalTrials.gov registry record
Integrated Whole-Genome Analysis of Hematologic Disorders
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 35
- Enrollment target
NCT01108159: Completed study, sponsored by Stanford University.
NCT01108159 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01108159 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.
Interventions
- PROCEDURE Blood Draw
- PROCEDURE Skin Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-08-02 |
What the finished NCT01108159 record still lists
NCT01108159 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Blood Draw is the first listed.
NCT01108159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01108159 about?
NCT01108159 is a clinical study titled "Integrated Whole-Genome Analysis of Hematologic Disorders". We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and ...
What is the current status of trial NCT01108159?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2009-09. Estimated completion is 2013-08-02.
What interventions are being tested in trial NCT01108159?
The interventions under investigation include: Blood Draw (PROCEDURE), Skin Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01108159?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia